{
    "body": "What is the drug target for Simtuzumab?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23821193", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27939076", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26085906", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27232579"
    ], 
    "ideal_answer": [
        " These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601.", 
        " these results suggest that loxl2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from gs-607601.", 
        "Simtuzumab is a humanized monoclonal antibody drug that targets LOXL2"
    ], 
    "exact_answer": [
        "LOXL2"
    ], 
    "type": "factoid", 
    "id": "58a644e560087bc10a000027", 
    "snippets": [
        {
            "offsetInBeginSection": 1530, 
            "offsetInEndSection": 1767, 
            "text": " These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821193", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1490, 
            "offsetInEndSection": 1725, 
            "text": "These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821193", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1534, 
            "offsetInEndSection": 1770, 
            "text": "These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821193", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1296, 
            "offsetInEndSection": 1458, 
            "text": "Other potential agents will be silent information regulator protein Sirtuin and antifibrotic monoclonal antibody Simtuzumab against lysyl oxidase like molecule 2.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26085906", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1491, 
            "offsetInEndSection": 1727, 
            "text": "These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821193", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 294, 
            "offsetInEndSection": 446, 
            "text": " aim of this study was to study the safety and tolerability of simtuzumab, a monoclonal antibody directed against lysyl oxidase-like 2 (LOXL2) enzyme, i", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27232579", 
            "endSection": "abstract"
        }
    ]
}